NASDAQ:EWTX Edgewise Therapeutics Q3 2026 Earnings Results & Report $37.53 -0.15 (-0.40%) Closing price 04:00 PM EasternExtended Trading$38.59 +1.06 (+2.81%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Edgewise Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of $0.84 versus the -$0.5218 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeBefore Market OpensConference Call7:00 AM ET Edgewise Therapeutics EPS ResultsActual EPS$0.84Consensus EPS -$0.5218Beat/MissBeat by +$1.3618One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEdgewise Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$119.23 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEdgewise Therapeutics' Q4 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Edgewise Therapeutics Q3 2026 Earnings FAQ Did Edgewise Therapeutics beat earnings estimates for Q3 2026? Edgewise Therapeutics (NASDAQ:EWTX) reported earnings of $0.84 per share for Q3 2026, beating the consensus estimate of -$0.5218. The report was announced on Wednesday, November 4, 2026. When is Edgewise Therapeutics' next earnings date? Edgewise Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Edgewise Therapeutics on the company's earnings history page. Edgewise Therapeutics Earnings HeadlinesEdgewise Therapeutics Reports Third Quarter 2026 Financial Results3 hours ago | prnewswire.comEdgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesNovember 2 at 8:00 AM | prnewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 4 at 1:00 AM | Behind the Markets (Ad)Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC SaysOctober 27, 2026 | finance.yahoo.comWilliam Blar Initiates Coverage on Edgewise Therapeutics With Outperform RatingOctober 17, 2026 | finance.yahoo.comDoes Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?October 15, 2026 | finance.yahoo.comSee More Edgewise Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email. Email Address About Edgewise TherapeuticsEdgewise Therapeutics (NASDAQ:EWTX) is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited. Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is evaluating sevasemten in clinical studies involving patients with these disorders and other potential muscle-related conditions. The company is also developing EDG-7500, an investigational cardiac sarcomere modulator being studied for potential use in hypertrophic cardiomyopathy. Edgewise was founded in 2017 and is headquartered in Boulder, Colorado. Its programs are being advanced through clinical development intended to support potential treatment applications in patients in the United States and other international markets. Kevin Koch, Ph.D., serves as the company’s chief executive officer.View Edgewise Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
